Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for...
Read More
Prophylactic treatment regimens lead to improvements in health-related quality- of-life (HRQoL) among individuals with...
BAY 94‐9027 (damoctocog alfa pegol; Jivi®; Bayer AG, Germany) is an extended half‐life B‐domain–deleted,...
Factor VIII replacement products have improved the care of patients with hemophilia A, but...
BAY 94‐9027 (damoctocog alfa pegol; Jivi®; Bayer AG, Germany) is an extended half‐life B‐domain–deleted,...
Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for...
Prophylactic treatment regimens lead to improvements in health-related quality- of-life (HRQoL) among individuals with...
The current interest in recombinant factor VIII (rFVIII) products stems from the fact that...
Adeno-associated virus (AAV)-mediated gene therapy is a promising treatment option for patients with hemophilia...
Discrepancies among several assays results can be observed within the laboratory monitoring of FVIII...